Episode 22. Management of Low-Risk MDS

Blood Cancer Talks

Контент предоставлен Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

1+ y ago 1:03:46

MP3•Главная эпизода

In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA".
Here are the key studies discussed:

1. ASH choosing wisely:
https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely

2. International Consensus Classification (ICC):
https://pubmed.ncbi.nlm.nih.gov/35767897/

3. WHO classification 2022:
https://pubmed.ncbi.nlm.nih.gov/35732829/

4. IPSS-M:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008

5. Romiplostim in MDS:
https://pubmed.ncbi.nlm.nih.gov/29396092/

6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034

7. Luspatercept in MDS:
https://www.nejm.org/doi/full/10.1056/nejmoa1908892

8. Lenalidomide in MDS:

https://ascopubs.org/doi/10.1200/JCO.2015.66.0118

https://pubmed.ncbi.nlm.nih.gov/21753188/

9.Iron chelation therapy in MDS:

https://pubmed.ncbi.nlm.nih.gov/32203980/

56 эпизодов

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff